ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,322.17
0.26%
US Tech 100
18,160.40
0.25%
다우존스 지수
40,032.34
0.31%
Bitcoin
65,819.84
-0.66%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Aridis Pharmaceuticals Inc (ARDS)

  7. Aridis Pharmaceuticals Inc (ARDS) 뉴스

ARDS

Aridis Pharmaceuticals (ARDS)

Aridis Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ARDS
일자시간출처헤드라인심볼기업
2024/02/1410:02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2024/01/1620:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/12/1606:15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/11/0406:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/11/0405:15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/11/0319:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/09/1410:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/09/0805:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/2605:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0505:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0505:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0405:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0221:17GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2 Million OfferingNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0213:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/2119:49Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/2106:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1805:05GlobeNewswire Inc.Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1804:01Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1720:36Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1221:00GlobeNewswire Inc.Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/2319:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/2021:00GlobeNewswire Inc.Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/0919:13Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/0919:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/0905:05GlobeNewswire Inc.Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/05/3121:00GlobeNewswire Inc.Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignNASDAQ:ARDSAridis Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:ARDS

최근 히스토리

NYSE
BAC
Bank of America
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
ADDYY
Adidas (QX)
COIN
ETHUSD
Ethereum
CCOM
US500
US 500
USOTC
BNPQY
BNP Paribas (QX)
PM
XAUUSD
Gold vs US Dollar
AMEX
SPY
SPDR S&P 500
NASDAQ
AMZN
Amazon.com
NYSE
MRK
Merck
NYSE
MCD
McDonalds
FX
USDEUR
US Dollar vs Euro
AMEX
XLF
Financial Select Sector
COIN
SOLUSD
Solana
USOTC
BASFY
BASF (QX)
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유